Emerging Treatment Options for Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma – Enduring Webcast

Description

Program Description

---

Chronic lymphocytic leukemia (CLL) is a lymphoproliferative disease of neoplastic B cells, accumulating in the blood, bone marrow, lymph nodes, and spleen. CLL is the most common adult leukemia in Western countries. It is a disease of the elderly, with a median age at diagnosis of 72 years. As such, CLL clinical management is often challenging and highly individualized based on the age of patients, their comorbidities, and the biological features of CLL cells.

Mantle cell lymphoma (MCL) is a mature B-cell neoplasm with heterogeneous clinical behavior molecularly characterized by the constitutive overexpression of cyclin D1 and deregulation of different signaling pathways. SOX11 expression determines an aggressive phenotype associated with accumulation of many chromosomal alterations and somatic gene mutations. A subset of patients with the SOX11-negative leukemic non-nodal MCL subtype follows an initial indolent clinical evolution and may not require treatment at diagnosis, although eventually may progress to an aggressive disease.

Rapid therapeutic advances have changed the treatment landscape of CLL and MCL.

Intended Audience

---

Hematologists/oncologists, physician assistants, nurse practitioners, and nurses

Commercial Supporter

---

This activity is supported by an educational grant from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.